Novartis AG - ESG Rating & Company Profile powered by AI
The ESG score includes seventeen UN SDGs including: 'Clean Water & Sanitation', 'Industry, Innovation & Infrastructure' and 'Life below Water'. The report of Novartis AG leverages intelligence from across the web and also from available documents by Novartis AG. This dashboard contains a Q&A section on Novartis AG.
Novartis AG in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 7.7; made up of an environmental score of 8.0, social score of 7.0 and governance score of 8.0.
7.7
High ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| 1 | Xlife Sciences AG | 8.0 | High |
| 1 | Zim Laboratories Ltd | 8.0 | High |
| 140 | Novartis AG | 7.7 | High |
| 140 | Pfizer Inc | 7.7 | High |
| 140 | Juno Therapeutics Inc | 7.7 | High |
| ... | ... | ... | |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Novartis AG have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Novartis AG disclose current and historical energy intensity?
Sign up for free to unlockDoes Novartis AG report the average age of the workforce?
Sign up for free to unlockDoes Novartis AG reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Novartis AG disclose its ethnicity pay gap?
Sign up for free to unlockDoes Novartis AG disclose cybersecurity risks?
Sign up for free to unlockDoes Novartis AG offer flexible work?
Sign up for free to unlockDoes Novartis AG have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Novartis AG disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Novartis AG conduct supply chain audits?
Sign up for free to unlockDoes Novartis AG disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Novartis AG conduct 360 degree staff reviews?
Sign up for free to unlockDoes Novartis AG disclose the individual responsible for D&I?
Sign up for free to unlockDoes Novartis AG disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Novartis AG disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Novartis AG disclose water use targets?
Sign up for free to unlockDoes Novartis AG have careers partnerships with academic institutions?
Sign up for free to unlockDid Novartis AG have a product recall in the last two years?
Sign up for free to unlockDoes Novartis AG disclose incidents of discrimination?
Sign up for free to unlockDoes Novartis AG allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Novartis AG issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Novartis AG disclose parental leave metrics?
Sign up for free to unlockDoes Novartis AG disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Novartis AG disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Novartis AG disclose the pay ratio of women to men?
Sign up for free to unlockDoes Novartis AG support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Novartis AG disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Novartis AG reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Novartis AG involved in embryonic stem cell research?
Sign up for free to unlockDoes Novartis AG disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Novartis AG disclose its waste policy?
Sign up for free to unlockDoes Novartis AG report according to TCFD requirements?
Sign up for free to unlockDoes Novartis AG disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Novartis AG disclose energy use targets?
Sign up for free to unlockDoes Novartis AG disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Novartis AG have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Novartis AG
These potential risks are based on the size, segment and geographies of the company.
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.